Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$128.87+1.65%
Close 2026-07-07 · 1-day change
Reading MRK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRK free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading MRK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRK free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on expanding its oncology pipeline. The current thesis state is stable, supported by strong recent financial results and raised revenue guidance.
The market appears to have a neutral valuation stance on MRK, with a slight premium compared to peers. There is an expectations gap of 0.27, indicating that some growth potential is already factored into the stock.
Fundamentals are expected to remain strong, with management on track to meet revenue and EPS guidance despite a recent GAAP loss per share. However, there is a moderate risk as the company has missed earnings in recent quarters.
The thesis hinges on the performance of sector bellwethers like LLY, JNJ, and ABBV. If these companies continue to deliver strong results, MRK could benefit from positive sector momentum. Conversely, any misses from these peers could negatively impact MRK's outlook.
In the next 1-3 years, MRK's performance will likely depend on its ability to execute on its management priorities and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement. Additionally, recent acquisitions enhance the oncology pipeline. There are no current threats to the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Sales growth over 5% would show the company can meet its higher revenue goals.
Confirms:Q2 worldwide sales were over $17.1 billion. This shows more than 5% growth.
Disproves:Q2 worldwide sales were below $16.5 billion. This means growth is weaker.
Why it matters: Sales growth below this level could signal weakening demand for key products.
Confirms:Q2 sales growth reported below 5% year over year.
Disproves:Q2 sales growth exceeds 5% year over year.
Why it matters: KEYTRUDA brings in a lot of money. Its sales trends will affect overall results.
Confirms:KEYTRUDA sales growth remains above 8% year over year.
Disproves:KEYTRUDA sales growth falls below 5% year over year.
Why it matters: Earnings results will show how Merck is doing and what to expect.
Confirms one read:Earnings beat expectations, showing strong growth.
Confirms the other:Earnings did not meet expectations. This may show problems with growth.
Why it matters: Confirming EPS guidance would show management believes in future earnings. This is despite recent losses.
Confirms one read:Management maintains EPS guidance of $5.04-$5.16 for 2026 during Q2 earnings call.
Confirms the other:Management cut EPS guidance to below $5.00 during the Q2 earnings call.
Why it matters: Raising revenue guidance shows stronger sales and growth potential.
Confirms:Management raises revenue guidance in the next earnings call.
Disproves:Revenue guidance remains unchanged or is lowered in the next earnings call.
Why it matters: If this drug is approved, it will grow Merck's blood disease treatments and open new areas.
Confirms:FDA approves TERN-701 before the expected end of the acquisition.
Disproves:FDA denies approval or delays the decision on TERN-701.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: New approvals would make Merck's oncology portfolio stronger. This is important for company growth.
Confirms:Announcement of FDA approval for at least one new oncology treatment in 2026.
Disproves:No new oncology approvals announced by the end of 2026.
Why it matters: Good data from these trials could help Merck's cancer treatments and boost future sales.
Confirms:Successful Phase 3 data readouts from at least two oncology trials.
Disproves:Bad Phase 3 data from any cancer trial.